Explicyte Immuno-Oncology - Cancer Immunotherapy CRO Services
Cancer Immunotherapy CRO Services
In vitro
Tumor killing
Tumor sensitization
Activation & immune checkpoint inhibition
Antibody-dependent cell cytotoxicity (ADCC)
Tumor antigen-specific killing
Immuno-modulation
Immune cell activation
Immune cell migration
Mixed Lymphocyte Reaction (MLR)
Macrophage assays
TLS-GC reaction
Cytokine Release Syndrome
In Vivo
Responsiveness to immunotherapies
PD-1/PD-L1 Axis Blockade
CTLA-4 Blockade
Immunization
Syngeneic tumor models
Breast Cancer : 4T1
Breast Cancer : EMT6
Colon Cancer : CT26
Colon Cancer : MC38
Glioblastoma : GL261
Lung Cancer : Lewis LLC1
Pancreatic Cancer : Pan02
Renal Cancer : Renca
Sarcoma : MCA-205
Translational
Services
Target validation
Preclinical immune profiling
Biomarker Discovery & Testing for Immuno-Oncology
Technological platforms
Quantitative digital pathology
Spatial transcriptomics
Proteomics
Flow cytometry
Featured service
TLS Detection & Evaluation
About
About Explicyte
Science
News
Careers
Contact us
Toggle menu
Contact us
Posts classified under:
Biomarkers
Explicyte Immuno-Oncology
>
CRO Services
>
Biomarkers
View Details
Biomarker Discovery & Testing for Immuno-Oncology
WordPress Lightbox
